Format

Send to

Choose Destination
Psychiatry Res. 2018 Jan;259:385-391. doi: 10.1016/j.psychres.2017.08.060. Epub 2017 Aug 24.

Quality assessment of clinical practice guidelines on tic disorders with AGREE II instrument.

Author information

1
Department of Pharmacy, Evidence-based Pharmacy Center, West China second hospital, Sichuan University, No. 20, Third Section, Renmin Nan Lu, Chengdu, Sichuan 610041, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China.
2
Department of Pharmacy, Evidence-based Pharmacy Center, West China second hospital, Sichuan University, No. 20, Third Section, Renmin Nan Lu, Chengdu, Sichuan 610041, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China; West China school of pharmacy, Sichuan University, Chengdu, China.
3
Department of Pharmacy, Evidence-based Pharmacy Center, West China second hospital, Sichuan University, No. 20, Third Section, Renmin Nan Lu, Chengdu, Sichuan 610041, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China. Electronic address: zhlingli@sina.com.
4
Department of Pediatric Neurology, West China Hospital, Sichuan University, Chengdu, China.
5
Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu 730000, China.
6
The Fourth People's Hospital of Chengdu, China.

Abstract

To assess the methodological quality of existing clinical practice guidelines (CPGs) on the treatment of tic disorders (TDs) using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument and summarize the guideline recommendations. Five CPGs met our inclusion criteria. The mean percentages for the AGREE II domain scores were: scope and purpose 83.33% (95% confidence interval [CI], 77.78-94.44%), stakeholder involvement 62.22% (95% CI, 38.89-94.44%), rigor of development 47.08% (95% CI, 6.25-83.33%), clarity of presentation 87.78% (95% CI, 72.22-94.44%), applicability 56.67% (95% CI, 33.33-87.50%), and editorial independence 46.67% (95% CI, 8.33-91.67%). There were large differences among the five CPGs concerning the categorization of evidence and recommendations. The recommendations for drug therapy were similar in all five CPGs, although there was controversy in certain areas. The methodological quality of CPGs for TDs was acceptable in terms of scope and purpose, stakeholder involvement, and clarity of presentation. However, CPG developers need to pay more attention to rigorous development processes, applicability, and editorial independence. Developers of future CPGs should improve adherence to the AGREE II guidelines. In addition, high quality studies on the treatment of TDs are needed to provide more evidence for developing guidelines.

KEYWORDS:

AGREE II; Clinical practice guidelines; Tic disorders

PMID:
29120847
DOI:
10.1016/j.psychres.2017.08.060
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center